17 results about "Neural Growth" patented technology

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

In one aspect, methods of promoting asymmetric nerve growth and / or regeneration are described herein. In some embodiments, such a method comprises exposing a population of transected or severed nerves to a first molecular growth cue and to a second molecular growth cue. The population of transected nerves comprises one or more nerves of a first nerve type and one or more nerves of a second nerve type differing from the first nerve type. Additionally, the first molecular growth cue preferentially promotes growth of the first nerve type, as compared to the second nerve type. Similarly, the second molecular growth cue preferentially promotes growth of the second nerve type, as compared to the first nerve type. Moreover, the first molecular growth cue is spatially separated from the second molecular growth cue.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

The present invention discloses a reduced graphene oxide nerve conduit and a device for promoting peripheral nerve regeneration, belonging to the technical field of tissue engineering. The raw materials for preparing the reduced graphene oxide nerve conduit of the present invention include paramagnetic materials and gels. The present invention constructs a nerve conduit that mimics the hierarchical structure of peripheral nerves, greatly improving the bionic degree and biocompatibility of the nerve conduit. The present invention uses 3D printing technology. On the premise of simulating the inherent biological components of the neurilemma, rGO is added to the composite material to enhance electrophysiological properties, and different formulations of composite materials are constructed to promote the recovery of electrophysiological disorders caused by nerve injuries. The present invention utilizes the fact that a magnetic field can be used as a non-invasive and controllable biological stimulus to guide nerve growth, and its combination with rGO can produce a synergistic effect to enhance the biological effect of rGO. The possibility of postoperative complications is reduced, and the repair effect after nerve injury repair can be increased.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Provided herein are compositions comprising a copolymer comprising at least one sulfonatoalkoxy EDOT monomer (e.g. EDOT-S) or at least one cationic EDOT monomer and at least one heterocyclic monomer (e.g. an EDOT-OH monomer) and one or more bioactive peptide amphiphiles (PAs). The compositions provided herein find use in cell culture methods and in methods of promoting neural growth and maturation.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

The invention discloses an application of a Tribbles homologous protein 3 pseudokinase gene TRIB3 in preparation of a medicine for promoting nerve growth and regeneration. The invention proposes and verifies that the expression of the Tribbles homologous protein 3 pseudokinase gene TRIB3 can promote the growth of neuronal axons and the regeneration of damaged neuronal axons for the first time; the TRIB3 overexpression vector based on the adeno-associated virus can effectively treat nerve injury of rats, realizes regeneration of damaged axons, recovers sensory functions, and provides a new direction for research and development of drugs for promoting nerve growth and regeneration.

The invention discloses an application of a non-traditional myosin IF gene MYO1F in preparation of a peripheral nerve growth regulation and control medicine. The invention proposes and verifies that the expression of the non-traditional myosin IF gene MYO1F can effectively regulate and control the physiological activity of neurons of a peripheral nervous system for the first time, for example, the expression of the MYO1F is inhibited to effectively inhibit the proliferation and migration of Schwann cells; the invention provides a new direction for research and development of drugs for treating Schwann cell-derived diseases and diseases caused by nerve injury.

The invention discloses application of fibroblasts in preparation of a medicine for inhibiting nerve cell growth, and belongs to the technical field of biological medicine. Researches find that the fibroblasts can inhibit proliferation and differentiation of neural progenitor cells in vitro and also can inhibit growth of mature nerve cells, and obvious inhibition of nerves can be observed in an in-vivo mouse intervertebral disc degeneration model, so that the fibroblasts can be used for inhibiting abnormal ingrowth of nerves in the intervertebral disc degeneration process and relieving intervertebral disc degeneration.

The utility model discloses a nerve socketed pipe, which belongs to the technical field of medical instruments and comprises a socketed pipe body, two ends of the socketed pipe body are open, and a gradually-shrinking area, a straight area and a gradually-expanding area are sequentially arranged in the socketed pipe body. The nerve socketed pipe provided by the utility model is provided with the gradually-shrinking area, the straight area and the gradually-expanding area, the gradually-shrinking area and the gradually-expanding area are used as the guiding areas at the two ends of the nerve socketed pipe, and the straight area is used as the nerve recovery anastomosis area, so that in the nerve growth process, the nerve can be prevented from growing around in a divergent manner to form neuroma, and the influence on a patient is avoided.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a fusion protein with an Fc fragment, such as a toll-like receptor 3-Fc (TLR3-Fc). In some embodiments of the present disclosure, the target biomolecule is toll-like receptor 9-Fc (TLR9-Fc). In some embodiments of the present disclosure, the target biomolecule is deoxyribonuclease I-Fc (DNAse I-Fc). In some embodiments of the present disclosure, the target biomolecule is neural growth factor-Fc (NGF-Fc). In some embodiments of the present disclosure, the target biomolecule is insulin-Fc.

This invention discloses a neurofilament light chain protein derivative, biomaterial, and its applications. The neurofilament light chain protein derivative is a protein based on the neurofilament light chain protein or its homologous protein with the sequence shown in SEQ ID NO: 1, wherein one or more amino acid residues in the Coil 2B region have pharmaceutically acceptable modifications or mutations. This invention designs and constructs a neurofilament light chain protein K316Q mutant by acetylation-mimicking mutation of the neurofilament light chain protein, which exhibits significant effects in promoting nerve growth and regeneration. This mutant can enhance the stability and function of neurofilament networks, promote the expansion of axonal growth cones, and directly target the intrinsic growth capacity of neurons, demonstrating excellent clinical translational potential.